Bone Marrow Aspiration Tube Selection in Pediatric ITP
A lithium-heparin tube should NOT be used for bone marrow aspirate in a child with persistent immune thrombocytopenia—use EDTA tubes for routine morphologic examination and flow cytometry.
Why Bone Marrow Aspiration May Not Be Needed
The more fundamental question is whether bone marrow aspiration (BMA) is even indicated in your patient with persistent ITP. Current guidelines have significantly restricted BMA indications in pediatric ITP:
When BMA is NOT Required 1, 2:
- Typical presentation: Isolated thrombocytopenia with normal hemoglobin and white blood cell counts
- No atypical features: Absence of hepatosplenomegaly, lymphadenopathy, or bone pain
- Normal peripheral smear: No blasts or abnormal cells
- Persistent ITP (3-12 months duration) with otherwise typical features
The 2019 ASH guidelines 1 and 2010 International Consensus Report 2 emphasize that BMA should be reserved for atypical cases only. Research demonstrates that in children with typical ITP features, the yield for detecting leukemia is less than 1% 3. A 2024 study showed that increased guideline adherence has appropriately reduced unnecessary BMAs over the past 25 years 4.
When BMA IS Indicated 2:
- Atypical hematologic features (anemia, leukopenia, neutropenia outside normal ranges)
- Hepatosplenomegaly or lymphadenopathy
- Bone pain or systemic symptoms
- Abnormal peripheral smear findings
- Before initiating corticosteroid therapy (debated, but some centers still recommend)
- Failure to respond to appropriate ITP therapy
- Progressive cytopenias during follow-up
If BMA is Performed: Tube Selection
Critical caveat: The question specifically asks about lithium-heparin tubes, which are contraindicated for bone marrow aspiration in ITP evaluation because:
- Heparin interferes with morphologic assessment of bone marrow cells
- Flow cytometry requires EDTA anticoagulation for optimal cell preservation
- Cytogenetic studies require heparin-free specimens
Proper Tube Selection:
- EDTA (purple top): Primary tube for morphology, flow cytometry, and cell counts
- Heparin tubes (green top): Only if cytogenetic studies are specifically needed (NOT lithium-heparin for routine evaluation)
- No anticoagulant: For touch preparations and direct smears
Management of Persistent ITP in Children
For your patient with persistent ITP (3-12 months duration), the management approach parallels newly diagnosed ITP 2:
Treatment Strategy:
- Observation is appropriate if platelet count 20-30 × 10⁹/L without significant bleeding
- First-line options when treatment needed:
- IVIg (0.8-1 g/kg single dose): 80% response rate
- IV anti-D (50-75 μg/kg): 50-77% response rate
- Short-course corticosteroids (prednisone 1-2 mg/kg/d for maximum 14 days)
Second-line Options for Persistent/Chronic ITP 2:
- Rituximab (375 mg/m²/week × 4): 31-79% response rates
- Dexamethasone (28 mg/m²/d)
- Thrombopoietin receptor agonists (increasingly used, though pediatric data still evolving)
Avoid prolonged corticosteroid therapy and use cytotoxic drugs with extreme caution in children 2.
Key Clinical Pitfalls
- Don't reflexively perform BMA in persistent ITP without atypical features—this represents outdated practice 4
- Never use lithium-heparin tubes for bone marrow evaluation in suspected hematologic disorders
- Watch for evolving bone marrow failure: Two cases in one series developed aplastic anemia during follow-up, emphasizing the need for vigilant monitoring even without initial BMA 4
- Distinguish from HIT: If the child has recent heparin exposure, consider heparin-induced thrombocytopenia rather than ITP 5, 6